Ampreloxetine Funding - Schedule of Future Royalty Payment Contingencies (Details) - USD ($) $ in Thousands	2 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Development and Collaboration Agreement
Consideration allocated, less transaction costs of $0.5 million		$ 24,464
Interest accretion		424
Ending balance	$ 24,888	24,888
Ampreloxetine Royalty Rights
Development and Collaboration Agreement
Consideration allocated, less transaction costs of $0.5 million	24,464
Interest accretion	424
Ending balance	$ 24,888	24,888
Transaction costs		$ 500